Preview

Медицинский Совет

Расширенный поиск

Применение ингибиторов натрийглюкозного ко-транспортера 2-го типа от результатов клинических исследований до практического применения в России

https://doi.org/10.21518/2079-701X-2018-16-100-108

Полный текст:

Аннотация

В клинических исследованиях, в т. ч. и ингибиторов натрий-глюкозного ко-транспортера 2 типа (ИНГТ2), основной причиной для прекращения терапии является развитие побочных эффектов. Однако в реальной клинической практике появляются дополнительные факторы, которые оказывают влияние на прекращение терапии. В данной работе проведена оценка развития нежелательных явлений на фоне терапии ИНГТ2 эмпаглифлозином, выявлены факторы риска развития этих явлений, а также проанализированы причины прекращения лечения ИНГТ2 в реальной клинической практике. В исследование было включено 86 пациентов с сахарным диабетом 2 типа, которым впервые назначался ИНГТ2 эмпаглифлозин. За время исследования было зарегистрировано 24 (27,9%) случая побочных явлений: инфекции мочеполовой системы – 13 (15,1%) случаев, гипогликемии – 7 (8,1%) случаев, а также гипотензии – 4 (4,7%). Факторами риска развития побочных явлений в целом был женский пол, ИМТ ≥ 30 кг/м2 и снижение скорости клубочковой фильтрации < 60 мл/мин/1,73 м2. Терапия эмпаглифлозином была прекращена у 37,1% пациентов по следующим причинам: развитие побочных эффектов – 11,6%, неэффективность терапии – 8,1%, стоимость препарата – 13,9%, другие причины – 3,5%. Таким образом, в реальной клинической практике не только развитие побочных эффектов, но и социально-экономические факторы занимают важное место в формировании приверженности к лечению.

Об авторах

Д. А. Лебедев
ФГБУ «Национальный медицинский исследовательский центр имени В.А. Алмазова» Минздрава России
Россия
Санкт-Петербург


А. Ю. Бабенко
ФГБУ «Национальный медицинский исследовательский центр имени В.А. Алмазова» Минздрава России
Россия
Санкт-Петербург


Список литературы

1. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med, 2017 Jun 12. doi: 10.1056/NEJMoa1611925.

2. Zinman B, Wanner C, Lachin JM, et al. Empagli flozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med, 2015, 373: 2117-2128.

3. Mosley JF, Smith L, Everton E, Fellner C. SodiumGlucose Linked Transporter 2 (SGLT2) Inhibitors in the Management of Type-2 Diabetes: A Drug Class Overview. P T, 2015, 40: 451-462.

4. Vallon V, Platt KA, Cunard R et al. SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol, 2011, 22: 104–112.

5. Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, List JF. Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J Diabetes Complications, 2013, 27: 479-484.

6. Yang XP, Lai D, Zhong XY, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis. Eur J Clin Pharmacol, 2014, 70: 1149–1158.

7. Liakos A, Karagiannis T, Athanasiadou E, et al. Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab, 2014, 16: 984–93.

8. Carlson CJ, Santamarina ML. Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus. Expert Opin Drug Saf, 2016, 15: 1401–12.

9. Nicolle LE, Capuano G, Fung A, et al. Urinary tract infection in randomized phase III studies of canagliflozin, a sodium glucose co-transporter 2 inhibitor. Postgrad Med, 2014, 126: 7–17.

10. Yang XP, Lai D, Zhong XY, Shen HP, Huang YL. Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis. Eur J Clin Pharmacol, 2014, 70: 1149-58.

11. Zhang M, Zhang L, Wu B, Song H, An Z, Li S. Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Metab Res Rev, 2014, 30: 204-21.

12. Liakos A, Karagiannis T, Athanasiadou E, et al. Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab, 2014, 16: 984-93.

13. Taylor SI, Blau JE, Rother KI. SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab, 2015, 100: 2849‐2852.

14. Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care, 2015, 38: 1687-93.

15. Storgaard H, Bagger JI, Knop FK, Vilsbøll T, Rungby J. Diabetic ketoacidosis in a patient with type 2 diabetes after initiation of sodiumglucose cotransporter 2 inhibitor treatment. Basic Clin Pharmacol Toxicol, 2016, 118: 168-70.

16. Gelaye A, Haidar A, Kassab C, Kazmi S, Sinha P. Severe Ketoacidosis Associated with Canagliflozin (Invokana): A Safety Concern. Case Rep Crit Care, 2016, 2016: 1656182.

17. Rosenstock J, Ferrannini E. Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors. Diabetes Care, 2015, 38: 1638–1642. doi: 10.2337/dc15-1380

18. Hine J, Paterson H, Abrol E, Russell-Jones D, Herring R. SGLT inhibition and euglycaemic diabetic ketoacidosis. Lancet Diabetes Endocrinol, 2015, 3: 503-4.

19. Watts NB, Bilezikian JP, Usiskin K, et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab, 2016, 101: 157-66.

20. Ljunggren Ö, Bolinder J, Johansson L, et al. Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. Diabetes Obes Metab, 2012, 14: 990-9.

21. Taylor SI, Blau JE, Rother KI. Possible adverse effects of SGLT2 inhibitors on bone. Lancet Diabetes Endocrinol, 2015, 3: 8-10.

22. Mahaffey KW, Neal B, Perkovic V, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Fabbrini E, Sun T, Li Q, Desai M, Matthews DR. Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). CANVAS Program Collaborative Group. Circulation, 2018 Jan 23, 137(4): 323-334.

23. Watts NB, Bilezikian JP, Usiskin K, et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab, 2016, 101: 157-66.

24. Zinman B, Wanner C, Lachin JM, for the EMPAREG OUTCOME Investigators, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med, 2015, 373(22): 2117–28.

25. Tang H, Zhang X, Zhang J, et al. Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials. Diabetologia, 2016, 59: 2546-51.

26. Weir MR, Kline I, Xie J, et al. Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR). Curr Med Res Opin, 2014, 30: 1759-68.

27. Kohler S, Salsali A, Hantel S, et al. Safety and tolerability of empagliflozin in patients with type 2 diabetes. Clin Ther, 2016, 38(6): 1299-1313.

28. Yavin Y, Mansfield TA, Ptaszynska A, et al. Effect of the SGLT2 Inhibitor Dapagliflozin on Potassium Levels in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis. Diabetes Ther, 2016, 7: 125-37.

29. FDA Drug Safety Communication: FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR). http://www.fda.gov/Drugs/DrugSafety/ucm505860.htm. Accessed 16 Jun 2016.

30. Heyman SN, Khamaisi M, Rosen S, et al. Potential hypoxic renal injury in diabetics on SGLT-2 inhibitors: caution regarding concomitant use of NSAIDs and iodinated contrast media. Diabetes Care, 2017, 40(4): e40–1.

31. Cherney DZ, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation, 2014, 129(5): 587–97.

32. Storgaard H, Gluud LL, Bennett C, et al. Benefits and harms of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis. PLoS One, 2016, 11(11): e0166125.

33. Zinman B, Inzucchi SE, Lachin JM et al. Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk. Stroke, 2017 May, 48(5): 1218-1225. doi: 10.1161/STROKEAHA.116.015756.

34. Tang H, Fang Z, Wang T, et al. Meta-analysis of effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular outcomes and allcause mortality among patients with type 2 diabetes mellitus. Am J Cardiol, 2016, 118: 1774–1780.

35. Guillausseau PJ. Influence of oral antidiabetic drugs compliance on metabolic control in type 2 diabetes. A survey in general practice. Diabetes Metab, 2003, 29: 79-81.

36. Ho PM, Magid DJ, Masoudi FA, McClure DL, Rumsfeld JS. Adherence to cardioprotective medications and mortality among patients with diabetes and ischemic heart disease. BMC Cardiovasc Disord, 2006, 6: 48.

37. Currie CJ, Peyrot M, Morgan CL, et al. The impact of treatment noncompliance on mortality in people with type 2 diabetes. Diabetes Care, 2012, 35: 1279-1284.

38. McAdam-Marx C, Bellows BK, Unni S, et al. Impact of adherence and weight loss on glycemic control in patients with type 2 diabetes: cohort analyses of integrated medical record, pharmacy claims, and patient-reported data. J Manag Care Spec Pharm, 2014, 20: 691-700.

39. Ayyagari R, Wei W, Cheng D, Pan C, Signorovitch J, Wu EQ. Effect of adherence and insulin delivery system on clinical and economic outcomes among patients with type 2 diabetes initiating insulin treatment. Value Health, 2015, 18: 198-205.

40. Buysman EK, Liu F, Hammer M, Langer J. Impact of medication adherence and persistence on clinical and economic outcomes in patients with type 2 diabetes treated with liraglutide: a retrospective cohort study. Adv Ther, 2015, 32: 341-355.

41. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care, 2005, 43: 521-530.

42. Gibson TB, Song X, Alemayehu B, et al. Cost sharing, adherence, and health outcomes in patients with diabetes. Am J Manag Care. 2010, 16: 589-60

43. Zaccardi F, Webb DR, Htike ZZ, Youssef D, Khunti K, Davies MJ. Efficacy and safety of sodium glucose cotransporter 2 inhibitors in type 2 diabetes mellitus: Systematic review and network meta-analysis. Diabetes Obes Metab, 2016.

44. Carter BL. Dosing of antihypertensive medications in patients with renal insufficiency. J Clin Pharmacol, 1995, 35: 81–86.

45. Greenblatt DJ, Duhme DW, Allen MD, et al. Clinical toxicity of furosemide in hospitalized patients. A report from the Boston Collaborative Drug Surveillance Program. Am Heart J, 1977, 94: 6–13.

46. Lowe J, Gray J, Henry DA, et al. Adverse reactions to frusemide in hospital inpatients. Br Med J, 1979, 2: 360–362.

47. Sinclair AJ, Bode B, Harris S, et al. Efficacy and safety of canagliflozin in individuals aged 75 and older with type 2 diabetes mellitus: a pooled analysis. J Am Geriatr Soc, 2016, 64: 543–552.

48. Cha SA, Yun JS, Lim TS, et al. Severe hypoglycemia and cardiovascular or all-cause mortality in patients with type 2 diabetes. Diabetes Metab J, 2016, 40: e7.

49. Mattishent K, Loke YK. Bi-directional interaction between hypoglycaemia and cognitive impairment in elderly patients treated with glucose-lowering agents: a systematic review and meta-analysis. Diabetes Obes Metab, 2016, 18: 135–141.

50. Meneilly GS, Tessier DM. Diabetes, dementia and hypoglycemia. Can J Diabetes, 2016, 40: 73–76.

51. Zhao Y, Kachroo S, Kawabata H, et al. Association between hypoglycemia and fallrelated fractures and health care utilization in older veterans with type 2 diabetes. Endocr Pract, 2016, 22: 196–204.

52. Carlson CJ, Santamarina ML. Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus. Expert Opin Drug Saf, 2016, 15: 1401–12.

53. Nicolle LE, Capuano G, Fung A, et al. Urinary tract infection in randomized phase III studies of canagliflozin, a sodium glucose co-transporter 2 inhibitor. Postgrad Med, 2014, 126: 7–17.

54. Liakos A, Karagiannis T, Athanasiadou E, et al. Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab, 2014, 16: 984–93.

55. Johnsson KM, Ptaszynska A, Schmitz B, et al. Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J Diabetes Complications, 2013, 27: 479–484.

56. Nyirjesy P, Sobel JD, Fung A, et al. Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Curr Med Res Opin, 2014, 30: 1109–1119.

57. Bohannon NJ. Treatment of vulvovaginal candidiasis in patients with diabetes. Diabetes Care, 1998, 21: 451–456.

58. Rudofsky G, Baldycheva I, Johnsson E, et al. Genital infections and relation to body mass index in patients with type 2 diabetes mellitus treated with dapagliflozin. Diabetologia, 2015, 58: 759–P.

59. Johnsson KM, Ptaszynska A, Schmitz B, et al. Urinary tract infections in patients with diabetes treated with dapagliflozin. J Diabetes Complications, 2013, 27: 473–478.

60. Nicolle LE, Capuano G, Fung A, et al. Urinary tract infection in randomized phase III studies of canagliflozin, a sodium glucose co-transporter 2 inhibitor. Postgrad Med, 2014, 126: 7–17.

61. Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and metaanalysis. Ann Intern Med, 2013, 159(4): 262-274.

62. US Food and Drug Administration. FDA Drug Safety Communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. http://www.fda.gov/Drugs/DrugSafety/ucm475463.htm. Published January 7, 2016. Accessed June 10, 2016.


Просмотров: 54


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)